News headlines about Lumenis (NASDAQ:LMNS) have trended somewhat negative recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lumenis earned a daily sentiment score of -0.04 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 51.7885599154335 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the stock’s share price in the near future.
Lumenis Company Profile
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.
Further Reading: NASDAQ
Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.